Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Feb:155:106947.
doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30.

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel

Yaki Saciuk  1 , Jennifer Kertes  2 , Micha Mandel  3 , Beatriz Hemo  1 , Naama Shamir Stein  1 , Anat Ekka Zohar  4
Affiliations
Observational Study

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel

Yaki Saciuk et al. Prev Med. 2022 Feb.

Abstract

Development of an effective vaccine against Covid-19 is crucial to reducing infection. mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first FDA-approved vaccinations reporting high efficacy (95%) and minimal side effects. Evaluating effectiveness of BNT162b2 in a general population has been made possible after the implementation of a nation-wide vaccination program in Israel. This retrospective cohort study was carried out in Maccabi HealthCare services, Israel among 1.6 million members aged 16 and over. The population was divided into those who were at least seven days post- second vaccination and those who had not been vaccinated. Number of days till the end of the study or Covid-19 infection, Covid-19-related hospitalization and mortality was calculated for each participant between 18.1.2021 to 25.4.2021. Participants who had reached day eight after second vaccination during the study period could contribute days to both groups. Vaccine efficacy (VE) was calculated using a conditional Poisson model, controlling for age group, gender, hypertension, diabetes and obesity, fitted within clusters defined by geographical statistical area and calendar week. BNT162b2 was found effective for the total population group for infection, hospitalization and mortality, with adjusted VE of 93·0% (CI:92·6-93·4%), 93·4% (CI:91·9-94·7%) and 91·1% (CI:86·5-94·1%) respectively. VE for infection was lower for participants aged 75 and over, and for those with hypertension, diabetes and obesity. This study strengthens the evidence that the Pfizer-BioNTech vaccination is effective in preventing infection, hospitalization and mortality.

Keywords: Covid-19; Pfizer-BioNTech vaccine; mRNA BNT162b2; vaccine effectiveness.

PubMed Disclaimer

References

    1. Angeli F., Spanevello A., Reboldi G., et al. SARS-CoV-2 vaccines: lights and shadows. Euro. J. Int. Med. 2021;88:1–8. - PMC - PubMed
    1. Armstrong B.G., Gasparrini A., Tobias A. Conditional Poisson models: a flexible alternative to conditional logistic case cross-over analysis. BMC Med. Res. Methodol. 2014;14:122. doi: 10.1186/1471-2288-14-122. - DOI - PMC - PubMed
    1. Dagan N., Barda N., Kepten E., et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 2021;384(15):1412–1423. doi: 10.1056/NEJMoa2101765. - DOI - PMC - PubMed
    1. FDA Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020, FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine. 2020. https://www.fda.gov/media/144245/download December. Accessed June 14, 2021.
    1. Fu W., Li J., Scheet P. Covid-19 vaccine efficacy: accuracy, uncertainty and projection of cases. medRxiv. 2020 doi: 10.1101/2020.12.16.20248359. December. - DOI

Publication types